Ethel Codner

Ethel Codner
Born (1966-02-04) February 4, 1966 (age 60)
Santiago, Chile
OccupationsPediatric endocrinologist and academic
Academic background
EducationMedical Degree
Specialization in Pediatric Endocrinology
Alma materPontifical Catholic University of Chile
University of Chile
Academic work
InstitutionsUniversity of Chile

Ethel Codner is a pediatric endocrinologist and academic. She is a full professor in the Institute of Maternal and Child Research at the University of Chile.

Codner has conducted research in the areas of pediatric endocrinology, reproductive endocrinology, type 1 diabetes, and adolescent ovarian function. She received the first Early Career Award from the International Society for Pediatric and Adolescent Diabetes (ISPAD) in 2006 and was named among the 100 Women Leaders of 2017 by El Mercurio.

Education

Codner earned a medical degree from the Pontifical Catholic University of Chile in 1991. She completed her specialization in pediatrics in 1994 and in pediatric endocrinology in 1997 at the University of Chile.

Career

Codner began her academic career in 2000 at the Institute of Maternal and Child Research at the University of Chile, where she has held the title of full professor since 2014, and also practices as a medical specialist. She was the director of the Chilean Society of Endocrinology and Diabetes from 2011 to 2012, president of the Latin American Society of Pediatric Endocrinology in 2015, and co-editor of the ISPAD guidelines for the care of diabetes in children and adolescents in 2018 and 2022.

Research

Codner's research has focused on the impact of diabetes on the female reproductive process, especially during puberty, hyperandrogenism, ovarian function, and genetics. Her work characterized how the presence of type 1 diabetes affects ovulation,[citation needed] menses, and hyperandrogenism. She has also studied the age of normal puberty in healthy children, and also in those living with type 1 diabetes.

Codner's work linked type 1 diabetes with polycystic ovary syndrome (PCOS), speculating that the high systemic doses of insulin without portal delivery can be part of the explanation for the association, and discovered that female offspring of PCOS women had increased Anti-Müllerian hormone (AMH) during infancy and early childhood. Building upon this, she indicated that external systemic insulin therapy in women with insulin-dependent type 1 diabetes tends to create PCOS. She examined 42 women with type 1 diabetes and 38 control subjects matched for age and BMI for PCOS, using the ESHRE/ASRM diagnostic criteria. Her findings proposed that women with type 1 diabetes were presented with more signs of PCOS, such as higher androgens and menstrual disturbances. She also showed that young women exhibit findings suggestive of polycystic ovarian morphology (PCOM) in high prevalence, reflecting a usual variation of ovarian morphology and larger ovarian volumes during early adolescence.

In collaborative research, Codner evaluated the genetic aspects and management of neonatal diabetes. She has treated young infants with neonatal diabetes with high-dose sulfonylureas. In an ISPAD publication, she and co-authors recommended an individualized A1C goal of 7.0% for patients aged 25 or younger who have access to care, and 7.5% for those with increased risk of hypoglycemia or reduced accessibility to diabetes control facilities.

Awards and honors

Selected articles

References

  1. 1 2 3 4 "Dra. Ethel Codner Dujovne se incorporó como Miembro de Número". academiachilenademedicina.cl. Retrieved July 17, 2025.
  2. ↑ "Unidad de Endocrinología Infantil y Genética". idimi.cl. 10 November 2021. Retrieved July 21, 2025.
  3. ↑ "SLEP". slep-endocrino.com. 26 January 2016. Retrieved July 21, 2025.
  4. ↑ "La Dra. Ethel Codner se incorpora a la Academia Chilena de Medicina como Miembro de Número". soched.cl. 28 November 2024. Retrieved August 15, 2025.
  5. ↑ "Doctora Ethel Codner se integra como miembro de número de la Academia Chilena de Medicina". medicina.uchile.cl. 14 November 2024. Retrieved July 18, 2025.
  6. ↑ Zaimi, M.; Michalopoulou, O.; Stefanaki, K.; Kazakou, P.; Vasileiou, V.; Psaltopoulou, T.; Karagiannakis, D. S.; Paschou, S. A. (2024). "Gonadal dysfunction in women with diabetes mellitus". Endocrine. 85 (2): 461–472. doi:10.1007/s12020-024-03729-z. PMC 11291547. PMID 38353886.
  7. ↑ Bizzarri, C.; Benevento, D.; Ravà, L.; Patera, I. P.; Schiaffini, R.; Ciampalini, P.; Giannone, G.; Cappa, M. (2011). "Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index". Fertility and Sterility. 96 (6): 1497–1502.e1. doi:10.1016/j.fertnstert.2011.09.023. PMID 21982726.
  8. ↑ Claude, E. M.; Mengue Eba, B.; Ngo Um Sap, S.; Ndi Manga, A.; Dehayem, M.; Mendane Mekobe, F.; Bodieu, A.; Zemsi, S.; Ebong, E.; Boli Ongmeb, A.; Sobngwi, E.; Mbanya, J. C. (2023). "Pubertal Development of Children and Adolescents Living with Diabetes in Yaoundé (Cameroon)". Health Sciences and Disease. 24 (4).
  9. ↑ Rosenfield, Robert L.; Ehrmann, David A. (2016). "The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited". Endocrine Reviews. 37 (5): 467–520. doi:10.1210/er.2015-1104. PMC 5045492. PMID 27459230.
  10. ↑ Escobar-Morreale, Héctor F.; San Millán, José L. (2007). "Abdominal adiposity and the polycystic ovary syndrome". Trends in Endocrinology & Metabolism. 18 (7): 266–272. doi:10.1016/j.tem.2007.07.003. PMID 17693095.
  11. ↑ Sirmans, Susan M.; Pate, Kristen A. (2013). "Epidemiology, diagnosis, and management of polycystic ovary syndrome". Clinical Epidemiology. 6: 1–13. doi:10.2147/CLEP.S37559. PMC 3872139. PMID 24379699.
  12. ↑ Cho, Yoon Hi; Craig, Maria E; Donaghue, Kim C (2014). "Puberty as an accelerator for diabetes complications". Pediatric Diabetes. 15 (1): 18–26. doi:10.1111/pedi.12112. PMID 24443957.
  13. ↑ Wellons, M. F.; Matthews, J. J.; Kim, C. (2016). "Ovarian Aging in Women with Diabetes: An Overview". Maturitas. 96: 109–113. doi:10.1016/j.maturitas.2016.11.019. PMC 5268844. PMID 28041589.
  14. ↑ Hassan, Samar S.; Musa, Salwa A.; De Franco, Elisa; Frew, Russel Donis; Babiker, Omer O.; Mohamadsalih, Ghassan F.; Ibrahim, Areej A.; Abu Samra, Samar; Abdullah, Mohamed A. (2024). "Incidence, Phenotypes, and Genotypes of Neonatal Diabetes: A 16-Year Experience. The Rare Genetic Etiologies of Neonatal Diabetes Are Common in Sudan". Pediatric Diabetes. 2024 (1) 2032425. doi:10.1155/2024/2032425. PMC 12016844. PMID 40302952.
  15. ↑ Marakkar, S.; Soodhana, D.; Apala, S.; Gangan, R.; Anirudhan, V. K.; Anand, M. (2023). "Case of neonatal diabetes mellitus due to KCNJ11 mutation: Therapeutic implications of a genetic diagnosis". Pediatric Companion. 2 (2): 44–46. doi:10.4103/pedc.pedc_3_24.
  16. ↑ Battelino, Tadej; Danne, Thomas; Bergenstal, Richard M.; Amiel, Stephanie A.; Beck, Roy; et al. (2019). "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range". Diabetes Care. 42 (8): 1593–1603. doi:10.2337/dci19-0028. PMC 6973648. PMID 31177185.
  17. ↑ "ISPAD–Early Career Award". ispad.org. Retrieved August 5, 2025.
  18. ↑ "100 Mujeres Líderes 2017". economiaynegocios.cl. Retrieved July 17, 2025.
  19. ↑ "Dra. Ethel Codner Dujovne recibe el Premio Academia Chilena de Medicina para Investigación Médica 2021". academiachilenademedicina.cl. Retrieved July 17, 2025.
  20. ↑ "Nómina de Miembros". academiachilenademedicina.cl. Retrieved July 17, 2025.